对有症状多发性骨髓瘤患者诊断时及维持治疗前行磁共振成像与[18F]氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描的前瞻性评估:IFM/DFCI 2009试验中IMAJEM研究的结果
IMAJEM研究前瞻性纳入134例有症状多发性骨髓瘤患者,比较MRI与PET-CT在诊断时检出骨病变及预后价值。诊断时MRI阳性127/134(95%),PET-CT阳性122/134(91%;P=0.33)。RVD三周期后及维持治疗前PET-CT正常化与更好的PFS和OS相关,而MRI正常化无预后价值。
要点
- 诊断时MRI与PET-CT检出骨病变无差异(95% vs 91%,P=0.33)。
- RVD三周期后PET-CT正常化者30个月PFS为78.7% vs 56.8%。
- 维持治疗前PET-CT正常化与更好的PFS和OS相关。
核心结论
- 诊断时PET-CT与MRI在骨病变检出方面无差异。
- PET-CT是评估初诊骨髓瘤预后的有力工具。
研究设计与样本
- 前瞻性试验纳入134例有症状多发性骨髓瘤患者,接受来那度胺、硼替佐米和地塞米松(RVD)联合或不联合自体干细胞移植,随后来那度胺维持治疗。
- 在诊断时、RVD三周期后及维持治疗前进行PET-CT和MRI检查。
- 主要终点为诊断时MRI与PET-CT检出骨病变的比较;次要终点包括MRI和PET-CT对无进展生存(PFS)和总生存(OS)的预后影响。
主要发现
- 诊断时MRI阳性127/134例(95%),PET-CT阳性122/134例(91%;P=0.33)。
- RVD三周期后及维持治疗前MRI正常化不能预测PFS或OS。
- 基线PET-CT阳性者中32%在RVD三周期后PET-CT正常化,该组PFS改善(30个月PFS分别为78.7% vs 56.8%)。
- 基线PET-CT阳性者中62%在维持治疗前PET-CT正常化,与更好的PFS和OS相关。
- 诊断时髓外病变是PFS和OS的独立预后因素,而维持治疗前PET-CT正常化是PFS的独立预后因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT) are important imaging techniques in multiple myeloma (MM). We conducted a prospective trial in patients with MM aimed at comparing MRI and PET-CT with respect to the detection of bone lesions at diagnosis and the prognostic value of the techniques. Patients and Methods One hundred thirty-four patients received a combination of lenalidomide, bortezomib, and dexamethasone (RVD) with or without autologous stem-cell transplantation, followed by lenalidomide maintenance. PET-CT and MRI were performed at diagnosis, after three cycles of RVD, and before maintenance therapy. The primary end point was the detection of bone lesions at diagnosis by MRI versus PET-CT. Secondary end points included the prognostic impact of MRI and PET-CT regarding progression-free (PFS) and overall survival (OS). Results At diagnosis, MRI results were positive in 127 of 134 patients (95%), and PET-CT results were positive in 122 of 134 patients (91%; P = .33). Normalization of MRI after three cycles of RVD and before maintenance was not predictive of PFS or OS. PET-CT became normal after three cycles of RVD in 32% of the patients with a positive evaluation at baseline, and PFS was improved in this group (30-month PFS, 78.7% v 56.8%, respectively). PET-CT normalization before maintenance was described in 62% of the patients who were positive at baseline. This was associated with better PFS and OS. Extramedullary disease at diagnosis was an independent prognostic factor for PFS and OS, whereas PET-CT normalization before maintenance was an independent prognostic factor for PFS. Conclusion There is no difference in the detection of bone lesions at diagnosis when comparing PET-CT and MRI. PET-CT is a powerful tool to evaluate the prognosis of de novo myeloma.
引用
- Moreau P, Attal M, Caillot D, et al. Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017. PMID: 28686535. doi:10.1200/JCO.2017.72.2975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。